A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD

Inclusion Criteria for Main Study: * Males and females, from 0 (including newborns) to \< 18 years of age at time of randomization * Confirmed diagnosis of LC-FAOD * Have a caregiver(s) willing and able to assist in all applicable study requirements * Have a legally authorized representative willing and able to provide written informed consent after the nature of the study has been explained and prior to any research-related procedures, and the study participant to be able to provide age-appropriate written assent * Have ANY ONE of the following significant clinical manifestations of LC-FAOD: * At least 2 in the prior year, or 3 in the prior 2 years, of severe major episodes of metabolic decompensation (eg, hypoglycemia, rhabdomyolysis, or exacerbation of cardiomyopathy, requiring ER/urgent care unit visits or hospitalizations) * Recurrent symptomatic hypoglycemia (clinical symptoms of hypoglycemia) requiring intervention * Susceptibility to hypoglycemia after short periods of fasting (less than 4 to 12 hours, depending on age) * Evidence of functional cardiomyopathy requiring ongoing medical management or clinical manifestation of heart failure * Sibling(s) with the same pathogenic variant who presented with MCEs * Participant with pathogenic variants that are known or suspected to be associated with absent or severely reduced enzyme activity or with severe disease manifestations. * From the period following informed consent to 5 days after the last dose of stu…